An entirely dedicated structure, Pierre Fabre Oncology, with the unique mission of implementing clinical development and marketing the Group's anti-cancer drugs.
New Zealand Medical & Scientific represent Pierre Fabre Medicament a leading research based company in the area of oncology. The principle product developed by Pierre Fabre is Navelbine® (vinorelbine tartrate) a unique product which offers many advantages for people suffering from metastatic breast cancer and/or non small Cell Lung Cancer. Ongoing research into this product will mean that more people suffering from various cancers can experience the many benefits of therapy with Navelbine®.